Proteasome Inhibitors Market

The market for proteasome inhibitors is experiencing rapid transformation. Amgen’s acquisition of Onyx Pharmaceuticals, developer of Kyprolis, for $10.4 billion comes just five years after Takeda paid $8.8 billion for Millennium Pharmaceuticals, developer of Velcade, the first in class.

Growing evidence from translational research coupled with evidence from both clinical trials and outcome research have established the proteasome as a novel and legitimate therapeutic target and enabled the rapid development of a second-generation orally available proteasome inhibitors.

Proteasome Inhibitors Market report analyzes both the technology and current market landscape and evaluates both approved and in-development second generation proteasome inhibitor molecules with emphasis on Bortezomib, Carfilzomib, Oprozomib, Ixazomib, Marizomib and Delanzomib.

Proteasome Inhibitors Market report examines Amgen’s acquisition of Onyx and Takeda’s acquisition of Millennium and volunteers a forecast to 2020. Companies profiled in the report include Amgen, Johnson & Johnson, Takeda, Teva , Onyx and Nereus.

Published: October 2013
Format: PDF by eMail
Pages: #12
Author: BioReports

Contents:

1.    Hematological Cancer Therapies Market
2.    Proteasome Inhibitors
2.1   Velcade (bortezomib)
2.2   Krypolis (carfilzomib)
3.    Proteasome Inhibitors Market
4.    Second Generation Proteasome Inhibitors
5.    Proteasome Inhibitors Market Forecast

Table & Figures:

1.    Hematological Cancer Therapies Market Forecast (2013 – 2020)
2.    Commercially Available Proteasome Inhibitors
3.    Velcade Sales Segmented by Marketing Company (2008 – 2013)
4.    Krypolis 2012 - 2013 Quarterly Sales
5.    Proteasome Inhibitors Market Revenue & Growth Rate (2008 - 2013)
6.    Second Generation Proteasome Inhibitors in Clinical Development
7.    Proteasome Inhibitors Market Forecast (2014 - 2020)